Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study - Naoyuki, K; Shin, F; Toshikazu, H (J Clin Rheumatol, 2011)
Jun